Sonoma Pharmaceuticals Netherlands B.V. is a wholly owned subsidiary of Sonoma Pharmaceuticals, Inc. and was founded in 2003.

Sonoma Pharmaceuticals Netherlands directs the marketing, sales and customer service divisions for Europe.  We have adopted a market acquisition strategy that employs a regionally segmented distributor network. We are focused on maintaining customers’ satisfaction, generating market awareness and supporting the commercialization of Microcyn® Technology-based products throughout Europe.

Since its approval according to the European Medical Devices Directive (93/42/EEC) in November 2004, Dermacyn® Wound Care has become a standard of care in dermatology and advanced wound treatment. This clinically proven wound treatment solution is routinely used in wound care centers, hospitals and nursing homes throughout Europe.

Building on the success of Dermacyn Wound Care, we introduced our new advanced CE Mark-approved wound care product line, Microdacyn®, in March 2014.

With the introduction of our wound care hydrogel, as well as the addition of smaller bottle configurations for the advanced wound care solution, we strongly believe the use of Microdacyn® advanced wound care products will play an even more prominent role in wound care in the future.

Microdacyn® advanced wound care products are being used for the treatment of acute and chronic wounds: e.g. diabetic foot ulcers, pressure sores, venous ulcers, post-radiation wounds and burns including those located in any human cavity like the oral, nasal or ear.

The combination of high efficacy, excellent performance, broad application within a comprehensive wound treatment regimen and unparalleled safety for patient, medical practitioner and environment makes this ready-to-use, shelf-life stable formula a revolutionary breakthrough in advanced wound care.